Jail-Based Medication Assisted Treatment

Sergio Huerta, MD
Medical Director
Recovery Services of New Mexico (RSONM)
What is Opioid Use Disorder (OUD) ?

• OUD is a chronic medical illness characterized by compulsive use of opioids even when a person wants to stop or when using opioids negatively affects a person’s physical and emotional well-being.

• It is a brain disease that impacts areas of the brain that control motivation, impulse control, reaction to stress, memory and decision making. These changes last a long time, even after a person stops using opioids.

• Like diabetes or heart disease, there is no cure for addiction, but it can be treated and people with addiction can and do recover. Without treatment, addiction can continue to get worse.
Opioid Use Disorder (OUD) in New Mexico

10% of New Mexicans are living with a substance use disorder (SUD)\textsuperscript{12}

- 205,000 New Mexicans with SUD
- 39,000 New Mexicans with opioid use disorder (OUD)

Only 35% of New Mexicans with an SUD are receiving treatment\textsuperscript{12}

- 134,000 New Mexicans need treatment

In 2020, New Mexico had its highest drug overdose (OD) death rate – 766 deaths\textsuperscript{20}

- Majority (66%) attributed to opioids
Incarcerated Individuals with OUD

Prisoners and jail inmates released to the community are between 10 to 40 times more likely to die of an opioid overdose than the general population\(^\text{16}\)

The U.S. has the second-highest incarceration rate in the world and the societal costs are estimated to be as high as $1.7 trillion annually\(^\text{7}\)

Nearly two-thirds of persons who are incarcerated have a history of SUD\(^\text{14}\)
Incarcerated Individuals with OUD in NM

The number of inmates admitted to the prison system for drug possession in NM increased by 18% over the last decade\textsuperscript{13}

NM three-year recidivism rate was 54% in FY19 and FY20 with substance use as one of the main drivers for return to prison after release\textsuperscript{13}
Medication Assisted-Treatment (MAT)

Three generic FDA approved medications for the treatment of OUD

1. Methadone
2. Buprenorphine (brand name of buprenorphine/naloxone formulation - Suboxone)
3. Naltrexone (brand name of extended-release formulation - Vivitrol)

Multidisciplinary team to deliver evidence-based services

• Counseling
• Case management
• Drug testing
MAT Benefits

• Reduce mortality and overdose
• Reduce opioid use
• Increase retention in treatment
• Decrease illicit opioid use and other criminal activity
• Increase patient’s ability to gain and maintain employment
• Improve infectious disease outcomes
• Improve birth outcomes for women who have OUD and are pregnant
Jail-based MAT: Benefits

Inmates who received methadone during incarceration were:

• More likely to engage in treatment post-release \(^{11}\)
• Less likely to use opioids post-release \(^{11}\)
• Had reduced odds of injection substance use post-release \(^{11}\)
• Reduced contraction of communicable diseases \(^{16}\)
• Experience less withdrawal and suffering

Provision of MAT reduced the rate of fatal OD among recently released individuals by more than 60\(^{10}\)
Jail-based MAT: Support

“The standard of care for all persons who are detained or incarcerated.”
– American Society of Addiction Medicine

“There is overwhelming evidence that medication-assisted treatment is an effective intervention for addressing OUD in criminal justice populations.” – SAMHSA

“A central component of the contemporary standard of care for the treatment of OUDs.” – National Sherriff's Association
Jail-based MAT: Reality

Only 30 out of 5,100 (0.5%) prisons and jails offered methadone or buprenorphine in 2017\textsuperscript{16}

Only 14 states offered methadone or buprenorphine maintenance for jail or prison inmates in 2018\textsuperscript{16}
Jail-based MAT: State and Federal Barriers

Methadone can only be dispensed through an accredited opioid treatment program (OTP)

• Accreditation and regulation through various entities:
  • Substance Abuse and Mental Health Services Administration (SAMHSA), Commission on Accreditation of Rehabilitation Facilities (CARF), Drug Enforcement Agency (DEA), NM Board of Pharmacy

• Additional accreditation for jail OTPs:
  • National Commission on Correctional Health Care (NCCHC)
Jail-based MAT: State and Federal Barriers

Concerns about MAT costs
• Medication, staffing, training, certification, storage, etc.

Concerns about security
• Policies and staffing needed to reduce the risk of diversion

Lack of community-based MAT providers to provide services in correctional settings

Misunderstanding of MAT
• Stigma of “substituting one drug for another.”
Pioneering Jail-based MAT in NM

Through collaboration with the Bernalillo County Behavioral Health Services Department and Bernalillo County Metropolitan Detention Center (MDC):

• RSONM developed the first privately owned opioid treatment program (OTP) in a correctional facility in the nation

• One of only eleven programs accredited through the National Commission on Correctional Health Care (NCCHC)
History of RSONM MDC Program

2010: Methadone maintenance treatment (MMT) program
   • Continuing community methadone during incarceration

2017: Methadone induction program
   • Identifying untreated patients with OUD and starting them on methadone during incarceration

2021: Buprenorphine maintenance and induction program
   • Continuing community buprenorphine during incarceration
RSONM MDC Program: Components

• Screening
• Assessment
• Treatment – Medication and Counseling
• Re-entry
RSONM MDC Program: Components

Screening:

• MDC screens all inmates for OUD on intake
  • If on MMT in the community:
    • Dose is verified, enrolled in program
  • If not on MMT in the community:
    • RSONM staff identifies potential patients, and they are offered induction
    • Patients can also self request to be on program through kiosks at MDC
RSONM MDC Program: Components

Assessment:

• Potential patients are assessed and enrolled into the program by RSONM multi-disciplinary team:
  • Intake coordinator
  • Nurse
  • Counselor
  • Physician (Addiction Psychiatrist)

• Collaborate with MDC partners:
  • Medical provider, correction officers, administration, security threat group and addiction treatment program (detox program)
RSONM MDC Program: Components

Treatment:
  • RSONM provides comprehensive treatment consisting of a combination of MAT and substance use counseling
  • Urine toxicology testing
RSONM MDC Program: Components

Re-entry:

• Follow-up care is coordinated at discharge with community OTP partners in Albuquerque, NM

• Harm reduction:
  • All patients receive naloxone (brand name Narcan) training
  • Leave with Narcan in-hand at time of release
RSONM MDC Program: Walkthrough

• Methadone is stored in a secure location
• Licensed staff pours medication in the secure area
• Nurse transports medication throughout MDC
  • One area (pod) of MDC at a time
• Nurse administers medication
  • Inspects mouth to ensure medication is consumed
• This cycle repeats for each jail pod/cell
Patient Dosing Process

Staff transporting methadone

Patient consuming methadone

Patient inspection

RSONM MDC Program: Walkthrough

• Average daily patient census:
  • 200-300 patients on methadone
  • 100-150 patients on buprenorphine

• Staff administers medications daily –weekends and holidays

• Physician completes inductions 6 days a week
Outcomes: Patients Treated

Oct 2021 to September 2022

• Methadone: 298 intakes

• Suboxone:
  • Maintenance: 203
  • Inductions: 111


Outcomes: Reduces Recidivism

Inmates with OUD on MMT compared to those with OUD who underwent detoxification:

• MMT inmates were less likely to be rebooked (53.4% vs 72.2%)\textsuperscript{20}

• MMT inmates had longer time periods between rebooking (236.3 vs 257.6 days)\textsuperscript{20}
Outcomes: Cost-effective Treatment

• MMT inmates were incarcerated less days due to reduced recidivism (29.33 days less)\(^7\)

It costs less to provide jail-based MMT than the subsequent cost associated with higher recidivism:

• Average per-day cost of incarceration is $116.49

• Costs $23.49 to prevent an incarcerated day using jail-based MMT\(^7\)
Outcomes: Patient Success

“Without all of you and this program, my success would not have been possible. I want to thank you for your efforts and dedication to really changing people's lives. I never thought I would ever see the day that drugs don’t cross my mind anymore. I was given a second chance at the life I deserve and want you to know that I share this success with you. I couldn’t have done it without you. Today I am not only clean from heroin but shortly after my meth addiction followed suit. Thank you and I love you all! You have also helped me achieve these grades and my very first driver's license!”

- RSONM Methadone Induction Patient
Opportunities for Improving Access

• Legislative requests
  • Re-introduce legislation like HB-290 (2021), introduced by Representative Andrea Romero, that established that methadone-dependent inmates be provided with methadone therapy.

• Jail-based strategies
  • Expanding services to other jail systems
  • Expanding services to DOC facilities

• Community-based strategies
  • Bundled rates like Medicare model

• Utilizing opioid settlement funds
  • Funding for our jail-based and community-based strategies
Inmates with OUD are marginalized and have poor access to MAT and have higher risk of OD compared to the general population.

RSONM’s jail-based MAT program pioneered treatment for inmates with OUD, has been serving the community for over 10 years, treated thousands of patients and has been shown to reduce recidivism and be cost effective.

Our ask is to support strategies that increase access to treatment for people suffering from incarceration and for those in the community with OUD.
References


Thank you!

Sergio Huerta, MD
Medical Director
RSONM
shuerta@rsonm.com